Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa)
- PMID: 21489216
- PMCID: PMC3073198
- DOI: 10.1186/1476-069X-10-S1-S6
Preventing primary liver cancer: the HBV vaccination project in the Gambia (West Africa)
Abstract
The Gambia Hepatitis Intervention Study (GHIS) consisted in the progressive introduction of HBV plasma-derived vaccine in different zones of this African country during the period 1986-1990. The study was launched and coordinated by IARC and is one of the most effective examples of an intervention project that both substantially contributed to our knowledge and to the health of local populations. Similar intervention studies have been carried out in South-East Asia. The studies indicate that the natural history of HBV infection differs in different populations , having a direct relevance for the implementation of HBV vaccination programmes in various parts of the world.
© 2011 Montesano; licensee BioMed Central Ltd.
Similar articles
-
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer.Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3216-23. doi: 10.1158/1055-9965.EPI-08-0303. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18990765
-
Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study.J Med Virol. 2002 Jul;67(3):444-6. doi: 10.1002/jmv.10093. J Med Virol. 2002. PMID: 12116042 Review.
-
[Hepatocellular carcinoma: a preventable cancer].Epidemiol Prev. 1997 Apr-Jun;21(2):129-36. Epidemiol Prev. 1997. PMID: 9378180 Review. Italian.
-
20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West Africa.PLoS One. 2013 Sep 30;8(9):e75775. doi: 10.1371/journal.pone.0075775. eCollection 2013. PLoS One. 2013. PMID: 24098724 Free PMC article. Clinical Trial.
-
Hepatitis B vaccination: disease and cancer prevention-a Taiwanese experience.Clin Liver Dis. 2010 Aug;14(3):521-30. doi: 10.1016/j.cld.2010.05.010. Clin Liver Dis. 2010. PMID: 20638029
Cited by
-
A history of the treatment of primary liver cancer.Clin Liver Dis (Hoboken). 2024 May 3;23(1):e0147. doi: 10.1097/CLD.0000000000000147. eCollection 2024 Jan-Jun. Clin Liver Dis (Hoboken). 2024. PMID: 38707239 Free PMC article. Review. No abstract available.
-
Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma.Niger Med J. 2015 Jul-Aug;56(4):231-5. doi: 10.4103/0300-1652.165032. Niger Med J. 2015. PMID: 26759504 Free PMC article. Review.
-
Prevalence of hepatitis B infection in the Gambian population: A narrative review of recent developments.Prev Med Rep. 2023 Sep 7;36:102401. doi: 10.1016/j.pmedr.2023.102401. eCollection 2023 Dec. Prev Med Rep. 2023. PMID: 37719791 Free PMC article. Review.
-
The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma.Vaccines (Basel). 2022 May 17;10(5):793. doi: 10.3390/vaccines10050793. Vaccines (Basel). 2022. PMID: 35632549 Free PMC article. Review.
-
Hepatitis B virus sero-prevalence amongst pregnant women in the Gambia.BMC Infect Dis. 2019 Mar 15;19(1):259. doi: 10.1186/s12879-019-3883-9. BMC Infect Dis. 2019. PMID: 30876397 Free PMC article.
References
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] International Agency for Research on Cancer: Lyon, France; 2010.
-
- International Agency for Research on Cancer. Hepatitis Viruses. Vol. 59. Lyon: International Agency for Research on Cancer; 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; p. 45.
-
- International Agency for Research on Cancer. Hepatitis Viruses. Vol. 59. Lyon: International Agency for Research on Cancer; 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; p. 165.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical